黄夹苷B | 27127-79-3

• 物质功能分类: 天然产物 - 甾体化合物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 黄夹苷B
• 英文名称: Thevetin B
• 英文别名: 3-[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-3-[(2R,3S,4S,5S,6S)-3-hydroxy-4-methoxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
• CAS: 27127-79-3
• 化学式: C₄₂H₆₆O₁₈
• 分子量: 859.0
• InChiKey: GZVMBXDQUQRICT-RCGIHWJFSA-N

物化性质

• 沸点：
  1008.0±65.0 °C(Predicted)
• 密度：
  1.46±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  60
• 可旋转键数：
  10
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  273
• 氢给体数：
  9
• 氢受体数：
  18

文献信息

• Topical and oral formulations of cardiac glycosides for treating skin diseases
  申请人：Streeper Robert

  公开号：US20060205679A1

  公开（公告）日：2006-09-14

  The present invention provides method, preparation and use of a variety of pharmaceutical compositions containing at least one digitalis glycoside such as oleandrin, odoroside-A, neriifolin, proscillaridin-A, methyl-proscillaridin-A, digitoxin, digoxin alone or at least one digitalis glycoside complexed with cyclodextrins. In another aspect, the present invention provides an effective method to treat diseases in mammals. In yet another aspect, the present invention provides an effective method for treating skin diseases in a human or non-human animal.

  本发明提供了一种方法、制备和使用多种含有至少一种毛地黄苷类药物成分的药物组合物，例如奥利安定、奥多罗苷A、内里福林、普罗斯西拉里丁A、甲基普罗斯西拉里丁A、地高辛、地高辛或至少一种毛地黄苷类与环糊精络合的药物。另一方面，本发明提供了一种有效的方法来治疗哺乳动物的疾病。另一方面，本发明提供了一种有效的方法来治疗人类或非人类动物的皮肤疾病。
• Treatment of viral disease by glycosides
  申请人：TSUMURA & CO.

  公开号：EP0442744A2

  公开（公告）日：1991-08-21

  A use of a compound of the formula: wherein R₁, R₂, R₃ and R₄ are independently hydrogen atom or hydroxy group, R₅ is hydrogen atom, methyl, hydroxymethyl, or formyl group, R₆ is hydrogen atom or methyl group, R₇ is 2,5-dihydro-2-oxofuran-4-yl group, or 2-oxo-2H-pyran-4-yl group, and R₈ is hydrogen atom or sugar group, with the proviso that, when R₇ is 2,5-dihydro-2-oxofuran-4-yl, then R₈ is not hydrogen atom, or a 4,5-unsaturated compound corresponding thereto, as an active ingredient, for the manufacture of a medicament for the treatment of viral diseases.

  式化合物的用途： 其中 R₁、R₂、R₃ 和 R₄ 独立地为氢原子或羟基、 R₅ 是氢原子、甲基、羟甲基或甲酰基、 R₆ 是氢原子或甲基、 R₇ 是 2,5-二氢-2-氧代呋喃-4-基或 2-氧代-2H-吡喃-4-基，以及 R₈ 是氢原子或糖基、 但当 R₇ 是 2,5-二氢-2-氧代呋喃-4-基时，R₈ 不是氢原子、 或与之相对应的 4,5-不饱和化合物作为活性成分，用于制造治疗病毒性疾病的药物。
• Treatment for migraine
  申请人：Quartey Kingsley Yianomah

  公开号：US10149858B2

  公开（公告）日：2018-12-11

  The present invention relates to methods for the treatment of migraine headache, cluster headache, tension type headache, trigeminal neuralgia (trigeminal headache) and headache disorders. The methods comprise administration of specific cardiac glycosides: Thevetin A and or Thevetin B to a subject in need thereof a pharmaceutically suitable preparation, in the form of nasal spray and or other modes and methods that will ensure adequate intranasal dosage, a pharmaceutically suitable preparation of the said cardiac glycosides that is sufficient to have the most desirable therapeutic effect when used as a prophylaxis, as a treatment and ameliorating agent of migraine headache and others headache disorders.

  本发明涉及治疗偏头痛、丛集性头痛、紧张型头痛、三叉神经痛（三叉神经痛）和头痛疾病的方法。这些方法包括服用特定的强心苷：Thevetin A 和或 Thevetin B 以鼻腔喷雾剂的形式或其他模式和方法，向有需要的受试者施用药学上合适的制剂，以确保足够的鼻内剂量，这种药学上合适的制剂足以在用作偏头痛和其他头痛疾病的预防、治疗和改善剂时产生最理想的治疗效果。
• Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
  申请人：Azaya Therapeutics Inc.

  公开号：US20040082521A1

  公开（公告）日：2004-04-29

  The present invention provides methods, preparations, and uses of a variety of liposomal-digitalis glycoside compositions. The present invention also provides protein-stabilized nanoparticle formulations containing liposomal-digitalis glycosides such as Oleandrin, digitoxin, and digoxin with reduced toxicity, high drug to lipid ratio, long circulating time in the bloodstream and the ability to deliver the drug to tumor sites. In another aspect, the present invention provides an effective method to reduce the growth of cancers or reduce the incidence of metastases.

  本发明提供了各种脂质体-地高辛苷组合物的方法、制备和用途。本发明还提供了含有脂质体-地高辛苷（如奥利司琼、地高辛和地高辛）的蛋白质稳定纳米粒子制剂，具有毒性低、药物与脂质比高、在血液中循环时间长以及能将药物输送到肿瘤部位等特点。另一方面，本发明提供了一种减少癌症生长或降低转移发生率的有效方法。
• Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
  申请人：Singh U. Chandra

  公开号：US20050026849A1

  公开（公告）日：2005-02-03

  The present invention provides method, preparation and use of a variety of pharmaceutical composition containing at least one digitalis glycosides such as oleandrin, odoroside-A, neriifolin, proscillaridin-A, methyl-proscillaridin-A, digitoxin, digoxin and amorphous cyclodextrins. In another aspect, the present invention provides an effective method to reduce the growth of cancers or reducing the incidence of metastases. In yet another aspect, the present invention provides an effective method for treating diseases in a warm-blooded animal.

  本发明提供了含有至少一种洋地黄苷的多种药物组合物的方法、制备和使用，这些洋地黄苷如齐墩果素、臭苷-A、聂立夫林、前胡苷-A、甲基前胡苷-A、地高辛、地高辛和无定形环糊精。另一方面，本发明提供了一种减少癌症生长或降低癌症转移发生率的有效方法。又一方面，本发明提供了一种治疗温血动物疾病的有效方法。